AA
CRSP icon

Ancora Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Ancora Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$218K Sell
3,991
-25
-0.6% -$1.32K ﹤0.01% 711
2026
Q1 		$191K Hold
4,016
– – ﹤0.01% 728
2025
Q4 		$211K Hold
4,016
– – ﹤0.01% 727
2025
Q3 		$260K Sell
4,016
-150
-4% -$8.61K 0.01% 670
2025
Q2 		$203K Buy
4,166
+356
+9% +$13.8K ﹤0.01% 721
2025
Q1 		$130K Buy
3,810
+880
+30% +$37.3K ﹤0.01% 802
2024
Q4 		$115K Sell
2,930
-1,075
-27% -$50.8K ﹤0.01% 827
2024
Q3 		$188K Buy
4,005
+300
+8% +$15.2K ﹤0.01% 704
2024
Q2 		$200K Buy
3,705
+75
+2% +$4.34K 0.01% 660
2024
Q1 		$247K Buy
3,630
+650
+22% +$46.5K 0.01% 629
2023
Q4 		$187K Buy
2,980
+1,650
+124% +$91.2K ﹤0.01% 685
2023
Q3 		$60.4K Buy
1,330
+700
+111% +$36.2K ﹤0.01% 874
2023
Q2 		$35.4K Hold
630
– – ﹤0.01% 992
2023
Q1 		$28.5K Hold
630
– – ﹤0.01% 1046
2022
Q4 		$26K Hold
630
– – ﹤0.01% 1109
2022
Q3 		$41K Hold
630
– – ﹤0.01% 1143
2022
Q2 		$38K Hold
630
– – ﹤0.01% 1248
2022
Q1 		$40K Sell
630
-1
-0.2% -$63 ﹤0.01% 1332
2021
Q4 		$48K Sell
631
-75
-11% -$6.55K ﹤0.01% 1301
2021
Q3 		$79K Sell
706
-450
-39% -$56.5K ﹤0.01% 1045
2021
Q2 		$187K Hold
1,156
– – ﹤0.01% 765
2021
Q1 		$141K Sell
1,156
-219
-16% -$33.1K ﹤0.01% 790
2020
Q4 		$211K Buy
1,375
+1,025
+293% +$121K 0.01% 614
2020
Q3 		$29K Hold
350
– – ﹤0.01% 946
2020
Q2 		$26K Hold
350
– – ﹤0.01% 940
2020
Q1 		$15K Hold
350
– – ﹤0.01% 1104
2019
Q4 		$21K Buy
+350
New +$19.1K ﹤0.01% 1057

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Ancora Advisors's CRSP Position: Q2 2026 in Review

Ancora Advisors reduced its CRISPR Therapeutics (CRSP) stake by 0.62% in Q2 2026, selling an estimated $1.32K and leaving 3,991 shares worth $218K. The position accounts for ﹤0.01% of the portfolio, ranked #711.

Ancora Advisors first reported a position in CRSP in Q4 2019 and has held it in 27 quarters since. The position peaked at $260K in Q3 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Ancora Advisors held 3,991 shares of CRISPR Therapeutics worth $218K as of Q2 2026.
  • Ancora Advisors sold 25 CRISPR Therapeutics shares in Q2 2026, an estimated $1.32K.
  • CRISPR Therapeutics made up ﹤0.01% of Ancora Advisors's portfolio in Q2 2026, its #711 holding.
  • Ancora Advisors first reported a position in CRISPR Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • Ancora Advisors's CRISPR Therapeutics position peaked at $260K in Q3 2025.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Ancora Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.